Local anti-angiogenic therapy by magnet-assisted downregulation of SHP2 phosphatase.
Animals
Cell Line
Down-Regulation
Genetic Vectors
/ administration & dosage
Lentivirus
/ genetics
Magnets
/ chemistry
Mice
Mouse Embryonic Stem Cells
/ metabolism
Neovascularization, Pathologic
/ genetics
Neovascularization, Physiologic
Protein Tyrosine Phosphatase, Non-Receptor Type 11
/ genetics
RNA Interference
Transduction, Genetic
/ methods
Anti-angiogenesis
Embryonic stem cells
Gene therapy
Lentivirus
Magnetic nanoparticles
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 07 2019
10 07 2019
Historique:
received:
12
03
2019
revised:
03
05
2019
accepted:
19
05
2019
pubmed:
24
5
2019
medline:
12
9
2020
entrez:
24
5
2019
Statut:
ppublish
Résumé
Anti-angiogenic therapies are promising options for diseases with enhanced vessel formation such as tumors or retinopathies. In most cases, a site-specific local effect on vessel growth is required, while the current focus on systemic distribution of angiogenesis inhibitors may cause severe unwanted side-effects. Therefore, in the current study we have developed an approach for the local inhibition of vascularization, using complexes of lentivirus and magnetic nanoparticles in combination with magnetic fields. Using this strategy in the murine embryonic stem cell (ESC) system, we were able to site-specifically downregulate the protein tyrosine phosphatase SHP2 by RNAi technology in areas with active vessel formation. This resulted in a reduction of vessel development, as shown by reduced vascular tube length, branching points and vascular loops. The anti-angiogenic effect could also be recapitulated in the dorsal skinfold chamber of mice in vivo. Here, site-specific downregulation of SHP2 reduced re-vascularization after wound induction. Thus, we have developed a magnet-assisted, RNAi-based strategy for the efficient local inhibition of angiogenesis in ESCs in vitro and also in vivo.
Identifiants
pubmed: 31121282
pii: S0168-3659(19)30287-1
doi: 10.1016/j.jconrel.2019.05.031
pii:
doi:
Substances chimiques
Protein Tyrosine Phosphatase, Non-Receptor Type 11
EC 3.1.3.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
155-164Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.